Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn’s Disease and Ulcerative Colitis

期刊论文
发表日期：

2024年4月5日

查看全文

Kiran K. Motwani,
Madeline Alizadeh,
Ameer Abutaleb,
Jennifer Grossman,
Jennifer Wellington,
Raymond K. Cross,
Kirk Russ,
Meena Bewtra,
James Lewis,
Raymond Cross,
Uni Wong,
Scott Snapper,
Josh Korzenik,
Shrinivas Bishu,
Rick Duerr,
Sumona Saha,
Freddy Caldera,
Laura Raffals,
Richa Shukla,
Themistocles Dassopoulos,
Matthew Bohm,
Poonam Beniwal-Patel,
David Hudesman,
Lauren Brook,
Joel Pekow,
Elizabeth Scoville,
Matthew A. Ciorba,
Parakkal Deepak

摘要

Background

Patient-reported outcomes (PROs), such as the short CD activity index (sCDAI) and partial Mayo Score (PMS), are used to define clinical remission in IBD, but may not represent the true degree of inflammation and endoscopy is invasive. Non-invasive testing options include c-reactive protein (CRP) and fecal calprotectin (FCP).

Aim

The aim of this study was to assess the degree of correlation of non-invasive biomarkers with PROs and the impact other clinical variables can have on their levels.

Methods

We reviewed data collected from the prospective cohort, Study of a Prospective Adult Research Cohort with IBD (SPARC-IBD), comprised of over 3000 patients from 17 tertiary referral centers. Demographic and clinical variables were analyzed by disease type, disease severity was based on PROs, and baseline CRP and FCP were measured. For comparative analysis, we performed Fisher’s exact test and Welch’s t test, where p < 0.05 was significant.

Results

1547 patients were included; 63% had CD, 56% were female, with an average disease duration of 13.6 years. CRP and FCP were associated with symptom severity in inflammatory CD. CRP was useful to differentiate symptoms across different disease locations in CD, whereas FCP was associated with symptom severity in Crohn’s colitis only. For UC, FCP was able to distinguish symptom severity better in distal UC, whereas in extensive or pancolitis, it was useful only to distinguish severe symptoms from other categories of symptom severity.

Conclusion

PROs correlate with CRP and FCP; however, disease location and phenotype impact their ability to distinguish symptom severity.